Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker NPCE
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Martha Morrell CHIEF MEDICAL OFFICER | NPCE Neuropace, Inc. | Sale | 25,000 | $15.97 | $399.3K Sale | Form 4 ↗ |
| May 14, 2025 | Orbimed Advisors LLC 10% owner | NPCE Neuropace, Inc. | Sale | 34,000 | $15.94 | $542.0K Sale | Form 4 ↗ |
| May 14, 2025 | Orbimed Advisors LLC 10% owner | NPCE Neuropace, Inc. | Sale | 134,136 | $15.83 | $2.1M Sale | Form 4 ↗ |
| Feb 21, 2025 | Martha Morrell CHIEF MEDICAL OFFICER | NPCE Neuropace, Inc. | Sale | 78,334 | $13.72 | $1.1M Sale | Form 4 ↗ |
| Feb 20, 2025 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 5.27M | $9.40 | $49.5M Sale | Form 4 ↗ |
| Jan 30, 2025 | Martha Morrell CHIEF MEDICAL OFFICER | NPCE Neuropace, Inc. | Sale | 200 | $15.00 | $3,000 Sale | Form 4 ↗ |
| Jan 29, 2025 | Martha Morrell CHIEF MEDICAL OFFICER | NPCE Neuropace, Inc. | Sale | 100 | $15.00 | $1,500 Sale | Form 4 ↗ |
| Jan 24, 2025 | Martha Morrell CHIEF MEDICAL OFFICER | NPCE Neuropace, Inc. | Sale | 3,200 | $15.01 | $48.0K Sale | Form 4 ↗ |
| Oct 25, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 223,991 | $5.45 | $1.2M Sale | Form 4 ↗ |
| Oct 23, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 147 | $6.02 | $885 Sale | Form 4 ↗ |
| Oct 22, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 4,082 | $6.09 | $24.9K Sale | Form 4 ↗ |
| Oct 21, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 3,720 | $6.10 | $22.7K Sale | Form 4 ↗ |
| Oct 18, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 4,878 | $6.29 | $30.7K Sale | Form 4 ↗ |
| Oct 17, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 3,294 | $6.28 | $20.7K Sale | Form 4 ↗ |
| Oct 16, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 6,900 | $6.57 | $45.3K Sale | Form 4 ↗ |
| Oct 15, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 4,017 | $6.50 | $26.1K Sale | Form 4 ↗ |
| Oct 14, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 4,031 | $6.54 | $26.4K Sale | Form 4 ↗ |
| Oct 11, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 2,572 | $6.35 | $16.3K Sale | Form 4 ↗ |
| Oct 10, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 2,504 | $6.12 | $15.3K Sale | Form 4 ↗ |
| Oct 9, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 3,123 | $6.10 | $19.1K Sale | Form 4 ↗ |
| Oct 8, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 6,000 | $6.43 | $38.6K Sale | Form 4 ↗ |
| Oct 7, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 4,910 | $6.66 | $32.7K Sale | Form 4 ↗ |
| Oct 4, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 5,757 | $6.92 | $39.8K Sale | Form 4 ↗ |
| Oct 3, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 3,318 | $6.97 | $23.1K Sale | Form 4 ↗ |
| Oct 2, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 3,843 | $6.87 | $26.4K Sale | Form 4 ↗ |
| Oct 1, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 4,882 | $6.77 | $33.1K Sale | Form 4 ↗ |
| Sep 30, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 4,749 | $6.73 | $32.0K Sale | Form 4 ↗ |
| Sep 27, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 5,059 | $6.63 | $33.5K Sale | Form 4 ↗ |
| Sep 26, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 5,821 | $6.62 | $38.5K Sale | Form 4 ↗ |
| Sep 25, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 5,858 | $6.60 | $38.7K Sale | Form 4 ↗ |
| Sep 23, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 282 | $7.54 | $2,126 Sale | Form 4 ↗ |
| Sep 20, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 765 | $7.50 | $5,738 Sale | Form 4 ↗ |
| Sep 13, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 1,993 | $7.59 | $15.1K Sale | Form 4 ↗ |
| Sep 6, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 11 | $7.50 | $82.5 Sale | Form 4 ↗ |
| Sep 4, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 14 | $7.50 | $105 Sale | Form 4 ↗ |
| Sep 3, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 2,093 | $7.60 | $15.9K Sale | Form 4 ↗ |
| Aug 30, 2024 | KCK Ltd. 10% owner | NPCE Neuropace, Inc. | Sale | 4,314 | $7.76 | $33.5K Sale | Form 4 ↗ |
37 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:19 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances